Literature DB >> 26099982

Melanoma: CheckMate 067--frontline nivolumab improves PFS alone or in combination with ipilimumab.

Alessia Errico.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26099982     DOI： 10.1038/nrclinonc.2015.112

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245
  1 in total
  10 in total

Review 1.  Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.

Authors:  Michael J Nathenson; Anthony P Conley; Edward Sausville
Journal:  Oncologist       Date:  2017-09-21

2.  STINGel: Controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy.

Authors:  David G Leach; Neeraja Dharmaraj; Stacey L Piotrowski; Tania L Lopez-Silva; Yu L Lei; Andrew G Sikora; Simon Young; Jeffrey D Hartgerink
Journal:  Biomaterials       Date:  2018-02-06       Impact factor: 12.479

3.  Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer.

Authors:  Benjamin Goeppert; Lena Frauenschuh; Manuela Zucknick; Stephanie Roessler; Arianeb Mehrabi; Mohammadreza Hafezi; Albrecht Stenzinger; Arne Warth; Anita Pathil; Marcus Renner; Peter Schirmacher; Wilko Weichert
Journal:  Br J Cancer       Date:  2015-10-13       Impact factor: 7.640

4.  PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.

Authors:  Yayi He; Leslie Rozeboom; Christopher J Rivard; Kim Ellison; Rafał Dziadziuszko; Hui Yu; Caicun Zhou; Fred R Hirsch
Journal:  Med Sci Monit       Date:  2017-03-09

5.  Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma.

Authors:  Soheila Shirinbak; Randall Y Chan; Shilpa Shahani; Sakunthala Muthugounder; Rebekah Kennedy; Long T Hung; G Esteban Fernandez; Michael D Hadjidaniel; Babak Moghimi; Michael A Sheard; Alan L Epstein; Muller Fabbri; Hiroyuki Shimada; Shahab Asgharzadeh
Journal:  Oncoimmunology       Date:  2021-01-04       Impact factor: 8.110

6.  The Treatment for a Patient with Cancer of Unknown Primary: A Case Report.

Authors:  QingTao Ni; KaiJin Lu; Chi Pan; ShengBin Dai; Peng Wang
Journal:  Dose Response       Date:  2021-11-21       Impact factor: 2.658

7.  T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer.

Authors:  Keyi Jia; Yayi He; Rafal Dziadziuszko; Sha Zhao; Xiaoshen Zhang; Juan Deng; Hao Wang; Fred R Hirsch; Caicun Zhou; Hui Yu; Liping Zhang
Journal:  Transl Lung Cancer Res       Date:  2019-12

8.  Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition.

Authors:  Brittany B Campbell; Melissa A Galati; Simone C Stone; Alexandra N Riemenschneider; Melissa Edwards; Sumedha Sudhaman; Robert Siddaway; Martin Komosa; Nuno M Nunes; Liana Nobre; A Sorana Morrissy; Matthew Zatzman; Michal Zapotocky; Lazar Joksimovic; Sangeetha N Kalimuthu; David Samuel; Gary Mason; Eric Bouffet; Daniel A Morgenstern; Melyssa Aronson; Carol Durno; David Malkin; John M Maris; Michael D Taylor; Adam Shlien; Trevor J Pugh; Pamela S Ohashi; Cynthia E Hawkins; Uri Tabori
Journal:  Cancer Discov       Date:  2021-02-09       Impact factor: 39.397

Review 9.  A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers.

Authors:  George R Nahas; Nykia D Walker; Margarette Bryan; Pranela Rameshwar
Journal:  Breast Cancer (Auckl)       Date:  2015-11-02

10.  PD-1 blockade restores impaired function of ex vivo expanded CD8+ T cells and enhances apoptosis in mismatch repair deficient EpCAM+PD-L1+ cancer cells.

Authors:  Rajeev Kumar; Fang Yu; Yuan-Huan Zhen; Bo Li; Jun Wang; Yuan Yang; Hui-Xin Ge; Ping-Sheng Hu; Jin Xiu
Journal:  Onco Targets Ther       Date:  2017-07-13       Impact factor: 4.147
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.